In the pan-cancer analysis, patients had better OS with high CD8+, PD-1+, CD8+PD-1+, or FOXP3+ cells after risk factor adjustments (HR range, 0.48-0.74, 95% CI range, 0.39 to 0.90; all P = .0001; Table 1; HRs listed in the Data Supplement, Table S3). Here, FOXP3 is linked to cancer.